# Is there a role for apolipoprotein E in perinatal brain injury?

**Authors:** Savina Abraham-Pol, Ertan Mayatepek, Mark Dzietko

PMC · DOI: 10.1186/s40348-026-00223-6 · Molecular and Cellular Pediatrics · 2026-03-03

## TL;DR

This paper reviews how the APOE gene might influence brain injury in newborns and highlights the need for more research.

## Contribution

The paper systematically reviews the role of APOE genotype in perinatal brain injury and identifies gaps in current research.

## Key findings

- APOE alleles ε2 and ε4 may be linked to increased injury severity and worse outcomes in newborns.
- ApoE modulates neuroinflammation and vascular dysfunction in preclinical models.
- Current evidence is inconsistent and requires replication in larger studies.

## Abstract

Perinatal brain injury remains a major cause of neonatal morbidity and lifelong neurological disability. Despite advances in neonatal care, the molecular determinants that modulate vulnerability and recovery in the immature brain remain poorly defined. Genetic variation is increasingly recognized as a contributor to the heterogeneous susceptibility observed among affected infants. Among the genes implicated in neurodevelopmental outcomes, apolipoprotein E (ApoE) has emerged as a key regulator of lipid metabolism, neuroinflammatory signaling, and neuronal repair in the central nervous system.

This systematic review examines clinical studies linking APOE genotype to the occurrence, severity, and outcome of perinatal brain injury, including intraventricular hemorrhage, hypoxic–ischemic encephalopathy, and perinatal stroke, and integrates these findings with a narrative synthesis of experimental and mechanistic literature. Available human data remain limited and heterogeneous. While some studies suggest that the ε2 and ε4 alleles may be associated with increased susceptibility to severe injury and poorer outcomes, findings are inconsistent and require independent replication.

Preclinical studies further demonstrate that ApoE modulates glial activation, lipid and cholesterol transport, blood–brain barrier integrity, and neuronal survival following hypoxic–ischemic and inflammatory insults. Isoform-specific effects, especially associated with ApoE4, appear to exacerbate neuroinflammatory and vascular dysfunction. However, despite converging evidence from animal models and adult neurological disease, ApoE-dependent mechanisms in the developing brain remain insufficiently explored.

Overall, this review highlights APOE genotype as a plausible contributor to vulnerability following perinatal brain injury and underscores the need for large, well-characterized neonatal cohorts and developmentally appropriate mechanistic studies to inform future neuroprotective strategies.

The online version contains supplementary material available at 10.1186/s40348-026-00223-6.

## Linked entities

- **Genes:** APOE (apolipoprotein E) [NCBI Gene 348]
- **Proteins:** APOE (apolipoprotein E)
- **Diseases:** hypoxic–ischemic encephalopathy (MONDO:0006663)

## Full-text entities

- **Genes:** Cxcl2 (C-X-C motif chemokine ligand 2) [NCBI Gene 20310] {aka CINC-2a, GROb, Gro2, MIP-2, MIP-2a, Mgsa-b}, Vldlr (very low density lipoprotein receptor) [NCBI Gene 22359], Mapk1 (mitogen-activated protein kinase 1) [NCBI Gene 26413] {aka 9030612K14Rik, ERK, Erk2, MAPK2, PRKM2, Prkm1}, ABCA1 (ATP binding cassette subfamily A member 1) [NCBI Gene 19] {aka ABC-1, ABC1, CERP, HDLCQTL13, HDLDT1, HPALP1}, SDC2 (syndecan 2) [NCBI Gene 6383] {aka CD362, HSPG, HSPG1, SYND2}, Lrp1 (low density lipoprotein receptor-related protein 1) [NCBI Gene 16971] {aka A2mr, CD91, Lrp, b2b1554Clo}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, Slc2a1 (solute carrier family 2 (facilitated glucose transporter), member 1) [NCBI Gene 20525] {aka GT1, Glut-1, Glut1, M100200, Rgsc200}, ASS1 (argininosuccinate synthase 1) [NCBI Gene 445] {aka ASS, CTLN1}, PPIA (peptidylprolyl isomerase A) [NCBI Gene 5478] {aka CYPA, CYPH, HEL-S-69p}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, Nfkb1 (nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105) [NCBI Gene 18033] {aka NF-KB1, NF-kappaB, NF-kappaB1, p105, p50, p50/p105}, PRKCH (protein kinase C eta) [NCBI Gene 5583] {aka PKC-L, PKCL, PRKCL, nPKC-eta, uORF2}, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase) [NCBI Gene 3156] {aka LDLCQ3, LGMDR28, MYPLG}, Mapk8 (mitogen-activated protein kinase 8) [NCBI Gene 26419] {aka JNK, JNK1, Prkm8, SAPK1}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, FGB (fibrinogen beta chain) [NCBI Gene 2244] {aka HEL-S-78p}, Ocln (occludin) [NCBI Gene 18260] {aka Ocl}, Jun (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 16476] {aka AP-1, Junc, c-jun}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, OCLN (occludin) [NCBI Gene 100506658] {aka BLCPMG, PPP1R115, PTORCH1}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, Lrp8 (low density lipoprotein receptor-related protein 8, apolipoprotein e receptor) [NCBI Gene 16975] {aka 4932703M08Rik, ApoER2, Lr8b}, TAGLN3 (transgelin 3) [NCBI Gene 29114] {aka NP22, NP24, NP25}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, Tjp1 (tight junction protein 1) [NCBI Gene 21872] {aka ZO1}, H2-Ab1 (histocompatibility 2, class II antigen A, beta 1) [NCBI Gene 14961] {aka Abeta, H-2Ab, H2-Ab, I-Abeta, IAb, Ia-2}, Mmp9 (matrix metallopeptidase 9) [NCBI Gene 17395] {aka B/MMP9, Clg4b, Gel B, MMP-9, pro-MMP-9}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, TREM2 (triggering receptor expressed on myeloid cells 2) [NCBI Gene 54209] {aka AD17, PLOSL2, TREM-2, Trem2a, Trem2b, Trem2c}, LRP1 (LDL receptor related protein 1) [NCBI Gene 4035] {aka A2MR, APOER, APR, CD91, DDH3, IGFBP-3R}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, Pcsk9 (proprotein convertase subtilisin/kexin type 9) [NCBI Gene 100102] {aka FH3, HCHOLA3, Narc1, PC9}, Ldlr (low density lipoprotein receptor) [NCBI Gene 16835] {aka Hlb301}, P2RY12 (purinergic receptor P2Y12) [NCBI Gene 64805] {aka ADPG-R, BDPLT8, HORK3, P2T(AC), P2Y(12)R, P2Y(AC)}, NFKBIA (NFKB inhibitor alpha) [NCBI Gene 4792] {aka EDAID2, IKBA, MAD-3, NFKBI}, VLDLR (very low density lipoprotein receptor) [NCBI Gene 7436] {aka CAMRQ1, CARMQ1, CHRMQ1, VLDL-R, VLDLRCH}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, SQLE (squalene epoxidase) [NCBI Gene 6713], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, Ppia (peptidylprolyl isomerase A) [NCBI Gene 268373] {aka Cphn, CyP-18, CypA, SP18}
- **Diseases:** ischemic stroke (MESH:D002544), cerebral ischemia (MESH:D002545), vascular disease (MESH:D014652), ischemic damage (MESH:D017202), neurovascular dysfunction (MESH:D013901), sensory deficits (MESH:D012678), neurotoxicity (MESH:D020258), cardiovascular disease (MESH:D002318), infection (MESH:D007239), behavioral disorders (MESH:D001523), MCI (MESH:D060825), AD (MESH:D000544), Neuroinflammation (MESH:D000090862), asphyxia (MESH:D001237), edema (MESH:D004487), CNS injury (MESH:D002493), brain weight loss (MESH:D015431), toxicity (MESH:D064420), BBB (MESH:C536830), traumatic brain injury (MESH:D000070642), cerebrovascular disease (MESH:D002561), CP (MESH:D002547), epilepsy (MESH:D004827), Inflammation (MESH:D007249), cerebrovascular and neurodegenerative disease (MESH:D019636), excitotoxic injury (MESH:D014947), mitochondrial dysfunction (MESH:D028361), Perinatal Stroke (MESH:D066087), cerebral hemorrhage (MESH:D002543), brain damage (MESH:D001925), death (MESH:D003643), dyslipidemia (MESH:D050171), Brain Dysmaturation (MESH:D001927), intellectual disabilities (MESH:D008607), Perinatal Brain Injury (MESH:D001930), HI (MESH:D020925), small vessel disease (MESH:D059345), vascular fragility (MESH:D005600), neuronal dysfunction (MESH:D009461), Ischemia Encephalopathy (MESH:D007511), Hypoxia (MESH:D000860), endothelial (MESH:D005642), neurological disability (MESH:D009069), tissue damage (MESH:D017695), amyloid angiopathy (MESH:C538248), Cognitive Impairment (MESH:D003072), neurodevelopmental impairment (MESH:D009422), neonatal encephalopathy (MESH:D007232), Haemorrhage (MESH:D006470), neurological disease (MESH:D020271), hypoxic (MESH:D002534), GM-IVH (MESH:D000074042), Cerebellar Hemorrhage (MESH:D020201), WMI (MESH:D056784), brain hemorrhages (MESH:D020300), stroke (MESH:D020521), hemiplegia (MESH:D006429), amyloid (MESH:C000718787), neurodevelopmental disability (MESH:D007859), thromboembolic (MESH:D013923)
- **Chemicals:** Amino acid (MESH:D000596), FA (MESH:D005227), rapamycin (MESH:D020123), triglycerides (MESH:D014280), Oxygen Glucose (-), oxygen (MESH:D010100), potassium (MESH:D011188), glutamate (MESH:D018698), N-methyl-D-aspartic acid (MESH:D016202), cholesterol (MESH:D002784), glucose (MESH:D005947), steroid (MESH:D013256), ATP (MESH:D000255), water (MESH:D014867), staurosporine (MESH:D019311), Lipid (MESH:D008055), LPS (MESH:D008070)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Rodentia (rodent, order) [taxon 9989]
- **Mutations:** arginine instead of cysteine at position 112, cysteine instead of an arginine at position 158, cysteine residue at the position 112, C) for 150
- **Cell lines:** Mo3.13 — Homo sapiens (Human), Hairy cell leukemia, Cancer cell line (CVCL_1439)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12953799/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12953799/full.md

## References

7 references — full list in the complete paper: https://tomesphere.com/paper/PMC12953799/full.md

---
Source: https://tomesphere.com/paper/PMC12953799